XML 73 R63.htm IDEA: XBRL DOCUMENT
v3.25.1

Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details) $ in Thousands | 3 Months Ended
--- | ---
Mar. 31, 2025 USD ($)
Royalty and Commercial Payment Receivable Activities Under the Cost Recovery Method |
Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method | $ 56,349
Acquisition of Royalty and Commercial Payment Receivables, Cost Recovery Method | 4,395
Receipt of Royalty and Commercial Payments, Cost Recovery Method | (415)
Recognition of Contingent Consideration, Cost Recovery Method | 60,329
Contingent consideration under RPAs, AAAs, and CPPAs |
Balance at Beginning of Period, Contingent consideration under RPAs, AAAs, and CPPAs | 3,000
Royalty and Commercial Payment Receivable Activities Under the EIR Method |
Balance at Beginning of Period, Royalty and Commercial Payment Receivables, EIR Method | 19,733
Income from Purchased Receivables Under the EIR Method | 6,070
Receipt of Royalty and Commercial Payments, EIR Method | (11,706)
Payment of Sales-Based Milestone | 3,000
Balance at End of Period, Royalty and Commercial Payment Receivables, EIR Method | 17,097
Income |
Income from purchased receivables under the cost recovery method | 5,525
Income from purchased receivables under the EIR method | 6,070
Twist |
Royalty and Commercial Payment Receivable Activities Under the Cost Recovery Method |
Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method | 15,000
Recognition of Contingent Consideration, Cost Recovery Method | 15,000
Dare | XACIATO |
Royalty and Commercial Payment Receivable Activities Under the Cost Recovery Method |
Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method | 21,999
Receipt of Royalty and Commercial Payments, Cost Recovery Method | (2)
Recognition of Contingent Consideration, Cost Recovery Method | 21,997
LadRx | MIPLYFFA |
Royalty and Commercial Payment Receivable Activities Under the Cost Recovery Method |
Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method | 4,850
Receipt of Royalty and Commercial Payments, Cost Recovery Method | (413)
Recognition of Contingent Consideration, Cost Recovery Method | 4,437
Palobiofarma |
Royalty and Commercial Payment Receivable Activities Under the Cost Recovery Method |
Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method | 10,000
Recognition of Contingent Consideration, Cost Recovery Method | 10,000
Kuros |
Royalty and Commercial Payment Receivable Activities Under the Cost Recovery Method |
Balance at Beginning of Period, Royalty and Commercial Payment Receivables, Cost Recovery Method | 4,500
Recognition of Contingent Consideration, Cost Recovery Method | 4,500
Castle Creek Biosciences, Inc |
Royalty and Commercial Payment Receivable Activities Under the Cost Recovery Method |
Acquisition of Royalty and Commercial Payment Receivables, Cost Recovery Method | 4,395
Recognition of Contingent Consideration, Cost Recovery Method | 4,395
Viracta | OJEMDA |
Income |
Income from purchased receivables under the cost recovery method | 5,525
Affitech | VABYSMO |
Royalty and Commercial Payment Receivable Activities Under the EIR Method |
Balance at Beginning of Period, Royalty and Commercial Payment Receivables, EIR Method | 13,105
Income from Purchased Receivables Under the EIR Method | 5,817
Receipt of Royalty and Commercial Payments, EIR Method | (11,145)
Payment of Sales-Based Milestone | 3,000
Balance at End of Period, Royalty and Commercial Payment Receivables, EIR Method | 10,777
Income |
Income from purchased receivables under the EIR method | 5,817
Aptevo | IXINITY |
Royalty and Commercial Payment Receivable Activities Under the EIR Method |
Balance at Beginning of Period, Royalty and Commercial Payment Receivables, EIR Method | 6,628
Income from Purchased Receivables Under the EIR Method | 253
Receipt of Royalty and Commercial Payments, EIR Method | (561)
Balance at End of Period, Royalty and Commercial Payment Receivables, EIR Method | 6,320
Income |
Income from purchased receivables under the EIR method | $ 253

X
- References No definition available. + Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, assignment and assumption agreements, and commercial payment purchase agreements. Includes contingent consideration recognized under ASC 815 and measured at fair value as a current liability at the inception of the transaction. Also includes contingent consideration recognized under ASC 450 if it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Classified as current. + References No definition available. + Details
Name: | xoma_ContingentConsiderationUnderPurchaseAgreements
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | xoma_ContingentConsiderationUnderRpasAaasAndCppasActivitiesAbstract
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of income that is not accounted for under Topic 606, in accordance with the cost recovery method. + References No definition available. + Details
Name: | xoma_IncomeNotFromContractWithCustomerCostRecoveryMethod
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of income, not accounted for under Topic 606, in accordance with the effective interest rate method. Includes income from purchased receivables. + References No definition available. + Details
Name: | xoma_IncomeNotFromContractWithCustomerEffectiveInterestRateMethod
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty and commercial payment receivables under the cost recovery method. Includes both current and noncurrent royalty and commercial payment receivables under cost recovery method. + References No definition available. + Details
Name: | xoma_RightsReceivableCostRecoveryMethod
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Increase in rights receivable due to acquisition of royalty and commercial payment receivables under the cost recovery method. Includes both current and noncurrent rights receivable. + References No definition available. + Details
Name: | xoma_RightsReceivableCostRecoveryMethodAcquisitionOfPaymentReceivable
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Decrease in rights receivable due to receipt of royalty and commercial payments under the cost recovery method. Includes both current and noncurrent rights receivable. + References No definition available. + Details
Name: | xoma_RightsReceivableCostRecoveryMethodReceiptOfPayments
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase in royalty and commercial payment receivables under the cost recovery method due to recognition of contingent consideration. Includes both current and noncurrent rights receivable. + References No definition available. + Details
Name: | xoma_RightsReceivableCostRecoveryMethodRecognitionOfContingentConsideration
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty and commercial payment receivables under the EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable. + References No definition available. + Details
Name: | xoma_RightsReceivableEirMethod
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Increase in rights receivable due to payment of sales-based milestones under the EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable. + References No definition available. + Details
Name: | xoma_RightsReceivableEirMethodPaymentOfSalesBasedMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Decrease in rights receivable due to receipt of royalty and commercial payments under the EIR (Effective interest rate) method. Includes both current and noncurrent rights receivable. + References No definition available. + Details
Name: | xoma_RightsReceivableEirMethodReceiptOfPayments
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | xoma_RoyaltyAndCommercialPaymentReceivableActivitiesUnderCostRecoveryMethodAbstract
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | xoma_RoyaltyAndCommercialPaymentReceivableActivitiesUnderEirMethodAbstract
Namespace Prefix: | xoma_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_TwistBioscienceCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_DareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_XaciatoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_LadrxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_MiplyffaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_CastleCreekBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_TovorafenibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_VabysmoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AptevoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_IxinityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |